Benzinga | Sep 1, 2020 06:20AM EDT

BMO Capital Downgrades Akcea Therapeutics to Market Perform, Lowers Price Target to $18.15

BMO Capital analyst Do Kim downgrades Akcea Therapeutics (NASDAQ:AKCA) from Outperform to Market Perform and lowers the price target from $26 to $18.15.